Mitesh J. Borad, MD

home / authors / mitesh-j-borad-md

Articles

Dr Borad on the Initial Efficacy of RLY-4008 in FGFR2 Fusion–Positive Cholangiocarcinoma

Mitesh J. Borad, MD

June 20th 2023

Mitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.

Dr. Borad on the Use of Next-Generation FGFR Inhibitors in Cholangiocarcinoma and Urothelial Carcinoma

Mitesh J. Borad, MD

February 2nd 2023

Mitesh J. Borad, MD, discusses the unique mechanism of action of next-generation FGFR inhibitors like KIN-3248 and their potential effect on patient outcomes in cholangiocarcinoma and urothelial cancer.

Dr. Borad on the Next Steps for Research Evaluating RLY-4008 in FGFR2+ Cholangiocarcinoma

Mitesh J. Borad, MD

October 25th 2022

Mitesh Borad, MD, discusses the next steps for investigating RLY-4008 in cholangiocarcinoma harboring FGFR2 fusion or rearrangement.

The Critical Role of Molecular Profiling in Cholangiocarcinoma

Mitesh J. Borad, MD

July 15th 2020

Sponsored Content

Dr. Borad on the SARAH and SIRveNIB Studies in Hepatocellular Carcinoma

Mitesh J. Borad, MD

May 12th 2018

Mitesh J. Borad, MD, associate professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, discusses the results of the SARAH and SIRveNIB studies in patients with hepatocellular carcinoma.